PRGO
NYSE · Pharmaceuticals
Perrigo Co Plc
$10.25
+0.09 (+0.89%)
Financial Highlights (FY 2026)
Revenue
4.08B
Net Income
-1,367,985,592
Gross Margin
35.1%
Profit Margin
-33.5%
Rev Growth
-1.5%
D/E Ratio
1.24
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.1% | 35.1% | 30.7% | 30.7% |
| Operating Margin | -27.2% | -24.5% | 18.2% | 20.0% |
| Profit Margin | -33.5% | -31.8% | 17.4% | 17.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.08B | 4.14B | 733.03M | 632.45M |
| Gross Profit | 1.43B | 1.46B | 225.36M | 194.44M |
| Operating Income | -1,109,429,302 | -1,013,794,671 | 133.71M | 126.60M |
| Net Income | -1,367,985,592 | -1,250,062,983 | 127.46M | 109.75M |
| Gross Margin | 35.1% | 35.1% | 30.7% | 30.7% |
| Operating Margin | -27.2% | -24.5% | 18.2% | 20.0% |
| Profit Margin | -33.5% | -31.8% | 17.4% | 17.4% |
| Rev Growth | -1.5% | -1.5% | +2.0% | -3.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 392.57M | 392.57M | 149.00M | 136.39M |
| Total Equity | 316.56M | 316.56M | 768.79M | 740.72M |
| D/E Ratio | 1.24 | 1.24 | 0.19 | 0.18 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -785,338,600 | -757,510,072 | 189.96M | 150.29M |
| Free Cash Flow | — | — | 136.11M | 128.72M |